A recent study published in N*ature Medicine* in December 2025 has sounded the alarm on a growing global health crisis: diabetes. Far from being just a public health concern, diabetes now represents a substantial economic threat, with projected costs of $10.2 trillion between 2020 and 2050—equivalent to an annual 0.22% tax on global GDP.
The True Cost of Diabetes
The economic burden of diabetes extends far beyond healthcare bills. When informal caregiving—support from family and friends—is accounted for, the total burden skyrockets to $78.8 trillion, roughly 1.72% of annual global GDP. On average, this equates to a per capita cost of $1,157, though the numbers vary dramatically: from $99 in Sub-Saharan Africa to $6,497 in North America.
The highest absolute economic impact is projected in some of the world’s largest economies: the United States ($2.5 trillion), India ($1.6 trillion), and China ($1.0 trillion).
What Drives This Macroeconomic Threat?
- Human Capital Loss Diabetes significantly reduces labor supply due to premature mortality and chronic illness. In lower-income countries, the loss of productivity is the main driver of economic burden.
- Capital Diversion In high-income nations, nearly 40.5% of the total burden arises from redirecting savings and investment to cover expensive medical treatments, slowing economic growth.
- Demographic Shifts According to the International Diabetes Federation, by 2025 1 in 9 adults globally—approximately 11.1%—will be living with diabetes. Alarmingly, nearly half remain undiagnosed, increasing long-term healthcare and productivity costs.
Regional Vulnerabilities
Some regions face a disproportionately high relative burden. Small island states and high-income countries like American Samoa and Australia experience the largest GDP losses relative to their size. North America bears the heaviest regional hit—equivalent to a 0.39% annual tax on GDP, followed by Latin America and the Caribbean at 0.23%.
The Call to Action
“The economic cost of diabetes is no longer just a health issue—it is a global economic challenge. By investing in prevention, early detection, and innovative care models, we can protect human capital, reduce the financial burden, and enable communities to thrive,” says Gareth Presch, CEO and Founder of the World Health Innovation Summit (WHIS) and CEO of the Global Social Prescribing Alliance (GSPA).
The scale of diabetes’ economic impact demands urgent attention. Prevention, early diagnosis, and effective management are not just health imperatives—they are critical economic strategies. Investments in public health initiatives, social prescribing, and community-based interventions could significantly reduce both the human and economic toll of diabetes.
At WHIS, we are committed to highlighting innovations that tackle chronic disease at scale, helping communities and economies thrive in the face of growing health challenges. Diabetes is not only a personal health concern it is a global economic priority.